1. Home
  2. MXE vs ACRV Comparison

MXE vs ACRV Comparison

Compare MXE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mexico Equity and Income Fund Inc. (The)

MXE

Mexico Equity and Income Fund Inc. (The)

HOLD

Current Price

$13.61

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.57

Market Cap

52.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXE
ACRV
Founded
1990
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
52.4M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
MXE
ACRV
Price
$13.61
$1.57
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
2.7K
555.6K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
2.66%
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.27
$1.05
52 Week High
$14.30
$3.56

Technical Indicators

Market Signals
Indicator
MXE
ACRV
Relative Strength Index (RSI) 60.04 50.04
Support Level $12.04 $1.49
Resistance Level $14.30 $1.86
Average True Range (ATR) 0.26 0.11
MACD 0.12 0.00
Stochastic Oscillator 88.62 59.00

Price Performance

Historical Comparison
MXE
ACRV

About MXE Mexico Equity and Income Fund Inc. (The)

Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: